SmartCatch

High-Level Overview

SmartCatch refers to multiple entities in the technology space, with two primary companies matching the description: a French biotech firm developing CTC (circulating tumor cell) capture technology for liquid biopsy in oncology diagnostics, and a U.S.-based fishing technology company creating rugged hardware and software for sustainable commercial trawling.[1][2][4] The biotech SmartCatch (smartcatch.fr), founded in 2016 and headquartered in Toulouse, France, builds compact, portable microfiltration devices that isolate rare CTCs from whole blood without sample preparation, serving clinicians, researchers, pharmaceutical companies, and oncology settings to enable personalized cancer diagnosis, monitoring, and treatment.[1][4] It solves the challenge of capturing intact CTCs—key indicators of cancer metastasis—for multi-omic analysis, preserving clinical data with minimal loss.[1][4]

The fishing SmartCatch (smart-catch.com) develops products like DigiCatch (real-time HD video/sensor system), SmartNet (remotely controllable nets), and DigiServices (data analytics subscriptions) for trawlers, targeting commercial fishermen to reduce bycatch by up to 2%, avoid fines, and boost profitability in harsh marine environments.[2][3] A separate AI tool named SmartCatch from WorldFish (not a standalone company) aids small-scale fishers with photo-based species identification via mobile AI, but this is a research prototype under development.[5] Both core companies show growth momentum: the biotech through R&D collaborations (e.g., LAAS-CNRS and CHU de Rangueil), and fishing tech via field-tested products and sustainability focus.[1][2][3][4]

Origin Story

The French biotech SmartCatch emerged from seven years of R&D collaboration between LAAS-CNRS (a French research lab) and the urology service at CHU de Rangueil hospital, founded in 2016 as a private entity in Toulouse.[1][4] Its idea stemmed from advancing microfiltration to unlock CTC liquid biopsy, addressing limitations in capturing rare tumor cells intact for cancer care; early traction built on this academic-clinical partnership to create routine-use devices.[1][4]

The U.S. fishing SmartCatch was founded by Rob Terry (CTO with 20+ years in hardware/software from Xerox PARC, Silicon Graphics, and others), blending Silicon Valley engineering with fishermen expertise.[2][3] Key team includes software engineer Michael Gittelsohn, net expert Sara Skamser (Foulweather Trawl), and Captain TJ Durnan (34-year Bering Sea veteran and Deadliest Catch alum), whose Excalibur vessel tests products.[3] The concept arose from solving data gaps and bycatch in commercial trawling, evolving through rugged prototypes tested in Alaska's offshore conditions.[2][3]

Core Differentiators

Biotech SmartCatch (smartcatch.fr)

• No-prep CTC capture: Physically entraps CTCs via size/deformability in a single step from whole blood, avoiding sample loss and preserving integrity for oncology diagnostics.[1][4]
• Portable clinical tools: Compact, easy-to-use microfiltration devices for routine use in clinics, urology, and research, enabling multi-omic CTC analysis.[1][4]
• Precision medicine focus: Targets metastatic potential via intact CTCs, supporting personalized cancer care for clinicians and pharma.[4]

Fishing Tech SmartCatch (smart-catch.com)

• Real-time net control: DigiCatch provides HD video/lighting/sensors via standard trawler wiring; SmartNet allows wheelhouse release of unwanted catch, cutting bycatch 2%+.[2]
• Rugged, fisherman-led design: Built for extreme conditions with input from captains like TJ Durnan; converges tech with generational fishing know-how.[2][3]
• Data-driven sustainability: DigiServices organizes harvest data to dodge fines, closures, and waste, making fishing profitable and eco-friendly.[2]

Role in the Broader Tech Landscape

The biotech SmartCatch rides the liquid biopsy wave in precision oncology, where non-invasive CTC analysis is transforming cancer from tissue biopsies amid rising metastatic disease burdens; timing aligns with multi-omics advances and demand for accessible diagnostics in healthcare systems strained by oncology caseloads.[1][4] It influences ecosystems by enabling global researchers/pharma to access CTC data, accelerating drug personalization and outcomes in a $10B+ market.

Fishing SmartCatch taps sustainable aquaculture tech, countering overfishing, bycatch regulations, and climate pressures on $400B+ global fisheries; its timing leverages IoT/AI sensors amid quotas and closures, empowering trawlers (key protein source) while reducing environmental impact.[2][3] It shapes the marine tech landscape via profitability incentives for sustainability, tested in real fleets. WorldFish's AI SmartCatch extends this to small-scale fishers in low-resource areas, boosting data for climate-resilient decisions in Asia/Africa.[5]

Quick Take & Future Outlook

For biotech SmartCatch, expect commercialization ramps with clinical integrations and partnerships, fueled by oncology's shift to liquid biopsies; regulatory wins and omics expansions could position it as a diagnostics leader amid aging populations.[1][4] Fishing SmartCatch eyes fleet adoptions and AI enhancements (e.g., predictive bycatch), scaling via subscriptions as sustainability mandates tighten globally.[2][3] WorldFish's tool may deploy via Peskas platform, aiding data-poor fisheries.[5]

Trends like AI precision, climate adaptation, and regulatory pressures will propel both, evolving their roles from niche innovators to ecosystem staples—echoing the high-level promise of tech making biotech and fishing smarter, more precise, and sustainable.